Decrease of the incidence of human and canine visceral leishmaniasis after dog vaccination with Leishmune® in Brazilian endemic areas

Vaccine

Volumn 27, Issue 27, 2009, Pages 3505-3512

  Palatnik de Sousa, Clarisa B ^a   Silva Antunes, Ilce ^b   Morgado, Adilson de Aguiar ^b   Menz, Ingrid ^c   Palatnik, Marcos ^a   Lavor, Carlile ^d  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Center for Zoonoses Control   (Brazil)

^c ZOETIS   (United States)

^d UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Canine visceral; Control of visceral leishmaniasis; Dog culling; FML saponin vaccine; Human visceral leishmaniasis; Leishmaniasis; Leishmune ; Zoonotic visceral leishmaniasis

Indexed keywords

LEISHMANIA VACCINE; LEISHMUNE; UNCLASSIFIED DRUG;

ARTICLE; BRAZIL; DISEASE TRANSMISSION; DOG; ENDEMIC DISEASE; HUMAN; INCIDENCE; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; RISK REDUCTION; VACCINATION; VISCERAL LEISHMANIASIS;

ANIMALS; BRAZIL; DOG DISEASES; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INCIDENCE; LEISHMANIASIS VACCINES; LEISHMANIASIS, VISCERAL; VACCINATION; ZOONOSES;

EID: 67349143961     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.045     Document Type: Article

References (40)

1. Tesh R. Control of zoonotic visceral leishmaniasis. Is it time to change strategies?. Am J Trop Med Hyg 52 (1995) 287-292
2. Magalhães P.A., Mayrink W., Costa C.A., Melo M.N., Dias M., Batista S.M., et al. Calazar na zona do Rio Doce-Minas Gerais Resultados de medidas profiláticas. Rev Inst Med Trop São Paulo 22 (1980) 197-202
3. Ashford D.A., Badaró R., Eulalio C., Freire M., Miranda C., Zalis M., et al. Studies on the control of visceral leishmaniasis: validation of the Falcon assay screening test-enzyme linked immunosorbent assay (Fast-ELISATM) for field diagnosis of canine visceral leishmaniasis. Am J Trop Med Hyg 48 (1993) 1-8
4. Palatnik-de-Sousa C.B., Santos W.R., França-Silva J.C., Costa R.T., Barbosa Reis A., Palatnik M., et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am J Trop Med Hyg 65 (2001) 510-517
5. Palatnik-de-Sousa C.B., Melo L.M.B., Borja-Cabrera G.P., Palatnik M., and Lavor C.C. Improving methods for epidemiological control of canine visceral leishmaniasis based on a mathematical model. Impact on the incidence of the canine and human disease. An Acad Bras Ciênc 76 (2004) 583-593
6. Dietze R., Baptista Barros G., Teixeira L., Harris J., Michelson K., Falqueto A., et al. Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil. Clin Inf Dis 25 (1997) 1240-1242
7. Furtado Vieira J.B., and Coelho E.G. Leishmaniose visceral ou calazar: aspectos epidemiológicos e de controle. Rev Soc Bras Med Trop 31 (1998) 85-92
8. Machado Braga M.D., Coelho I.C.B., Lima Pompeu M., Evans T.G., Tavares M.I., Teixeira M.J., et al. Controle do calazar canino: comparação dos resultados de um programa de eliminação rápida de cães sororreagentes por ensaio imuno-enzimático com outro de eliminação tardia de cães sororreagentes por teste de imunofluorescência indireta de eluato de papel filtro. Rev Soc Bras Med Trop 31 (1998) 419-424
9. Borja Cabrera G.P., da Silva V.O., da Costa R.T., Barbosa Reis A., Mayrink W., Genaro O., et al. The FML-ELISA assay in diagnosis and prognosis of canine visceral leishmaniasis. Am J Trop Med 6 (1999) 296-301
10. Dye C. The logic of visceral leishmaniasis control. Am J Trop Med Hyg 55 (1996) 125-130
11. Courtenay O., Quinnell R.J., Garcez L.M., Shaw J.J., and Dye C. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Inf Dis 186 (2002) 1314-1320
12. Genaro O., Pinto J.A., Da Costa C.A., França-Silva J.C., Costa R.T., Silva J.C., et al. Phase III randomized double blind clinical trial on the efficacy of a vaccine against canine visceral leishmaniasis in urban area of Montes Claros, MG, Brazil. Mem Ins Osw Cruz 91 (1996) 116
13. Dunan S., Frommel D., Monjour L., Ogunkolade B.W., Cruz A., and Quilici M. Vaccination trial against canine visceral leishmaniasis. Parasite Immunol 11 (1989) 397-402
14. Mohebali M., Khamesipour A., Mobedi I., Zarei Z., and Fesharki R.H. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R., Iran. Vaccine 22 (2004) 4097-4100
15. Lemesre J.L., Holzmuller P., Gonçalves R.B., Bourdoiseau G., Hugnet C., Cavaleyra M., et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine 25 (2007) 4223-4234
16. ® vaccine blocks the transmission of canine visceral leishmaniasis. Absence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs. Vaccine 23 (2005) 4805-4810
17. Palatnik-de-Sousa C.B. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 26 (2008) 1709-1724
18. Palatnik-de-Sousa C.B., de Barbosa A.F., Oliveira S.M., Nico D., Bernardo R.R., et al. FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine. Expert Rev Vaccines 7 (2008) 833-851
19. da Silva V.O., Borja-Cabrera G.P., Correia Pontes N.N., Paraguai de Souza E., Luz K.G., Palatnik M., et al. A Phase III trial of Efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amarante RN). Vaccine 19 (2001) 1068-1081
20. Borja-Cabrera G.P., Correia Pontes N.N., da Silva V.O., Paraguai de Souza E., Santos W.R., Gomes E.M., et al. Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (São Gonçalo do Amarante). Vaccine 20 (2002) 3277-3284
21. Palatnik de Sousa C.B., Paraguai de Sousa E., Gomes E.M., and Borojevic R. The FML vaccine (fucose-manosse ligand) protects hamsters from experimental kala-azar. Ciênc Cult (J Braz Assoc Adv Sci) 46 (1994) 290-296
22. Santos W.R., Aguiar I.A., Paraguai de Souza E., de Lima V.F.M., Palatnik M., and Palatnik-de-Sousa C.B. Immunotherapy against murine experimental visceral leishmaniasis with the FML-vaccine. Vaccine 21 (2003) 4668-4676
23. Santos W.R., de Lima V.M.F., Paraguai de Souza E., Bernardo R.R., Palatnik M., and Palatnik de Sousa C.B. Saponins IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis. Vaccine 21 (2002) 30-43
24. Borja-Cabrera G.P., Cruz Mendes A., Paraguai de Souza W., Okada L.Y.H., Trivellato F.A.A., Kawasaki J.K.A., et al. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 22 (2004) 2234-2243
25. ® vaccine. Vaccine 25 (2007) 6176-6190
26. ® vaccine against canine visceral leishmaniasis in Brazil. Vaccine 25 (2007) 2180-2186
27. ®) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine 24 (2006) 2423-2431
28. ® vaccine against canine visceral leishmaniasis in Brazil. Vaccine 26 (2008) 4991-4997
29. Mendes C.O., Paraguai de Souza E., Borja-Cabrera G.P., Melo Batista L.M., Santos M.A., Parra L.E., et al. IgG1/IgG2 antibody dichotomy in sera of vaccinated or naturally infected dogs with visceral leishmaniasis. Vaccine 21 (2003) 2589-2597
30. Prefeitura de Belo Horizonte/Portal Internet. Saúde, leishmaniose. http://portal1.pbh.gov.br (January 7, 2009).
31. Ministério da Saúde-SINAN-Secretaria de Vigilância em Saúde, Manual de Vigilância e Controle da Leishmaniose Visceral, Editora Ministério da Saúde, 2003, Brasília-DF, 120pp.
32. Camargo M.E. Fluorescent antibody test for the serodiagnosis of American Trypanososmiasis Technical modification employing preserved culture forms of Trypanosoma cruzi in a slide test. Rev Inst Med Trop São Paulo 8 (1966) 227-235
33. Marano N., Rupprecht C., and Regnery R. Vaccines for emerging diseases. Rev Sci Tech 26 (2007) 203-215
34. Gradoni L., Foglia Manzillo V., Pagano A., Piantedosi D., De Luna R., Gramiccia M., et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine 23 (2005) 5245-5251
35. Paranhos-Silva M., Freitas L.A., Santos W.C., Grimaldi Jr. G., Pontes de Carvalho L., and Oliveira dos Santos A. A cross-sectional serodiagnostic survey of canine leishmaniasis due to Leishmania chagasi. Am J Trop Med Hyg 55 (1996) 39-44
36. Ashford D.A., David J.R., Freire M., David R., Sherlock I., Eulálio M.C., et al. Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg 59 (1998) 53-57
37. http://infolocal.prefeitura.sp.gov.br/index.php?page=tabela&assunto=249 (February 15, 2009).
38. Palatnik C.B., Previato J.O., Mendonça-Previato L., and Borojevic R. A new approach to phylogeny of Leishmania: species specificity of glycoconjugate ligands for promastigote internalization into murine macrophages. Parasite Res 76 (1990) 289-293
39. Rafati S., Nakhaee A., Taheri T., Taslimi Y., Darabi H., Eravani D., et al. Protective vaccination against canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and type II of L. infantum. Vaccine 23 (2005) 3716-3725
40. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). Guidelines for the evaluation of Plasmodium falciparum vaccines in populations exposed to natural infections. TDR/MAL/VAC/97. World Health Organization, Geneva, Switzerland.